Invivyd, Inc. (IVVD) announces the identification of VBY329, a novel monoclonal antibody candidate for preventing Respiratory Syncytial Virus (RSV) infections in newborns, infants, and children.
VBY329 demonstrates higher potency and improved resistance compared to standard RSV medicines.
The company aims to advance VBY329 towards IND readiness in the second half of 2026.
VBY329 Potency
Antiviral potency of VBY329 is 1.5-fold greater on average than nirsevimab and 1.2-fold greater than clesrovimab against established RSV strains.
Resistance Profile
VBY329 shows enhanced neutralization activity against RSV F protein variants resistant to nirsevimab, indicating up to 500-fold greater resistance compared to existing options.
Market Projection
The pediatric RSV prophylaxis market is expected to reach $3-$4 billion in annual revenues globally by 2030, creating significant growth opportunities for VBY329.
Future Development
Invivyd is exploring additional ultra-long half-life RSV antibodies as a potential alternative for elderly and immunocompromised populations.
- VBY329's characteristics predict extended in vivo half-life, potentially offering a wider protective window compared to current RSV treatments.
- The success of VBY329 in preclinical development positions Invivyd to address the significant market demand for effective RSV prevention in infants and children.
The selection of VBY329 as a potential best-in-class RSV antibody candidate marks a significant milestone for Invivyd, paving the way for advanced RSV prophylaxis with enhanced efficacy and resistance profiles.